roche__tree

EU approval for Roche’s Polivy combo in relapsed/refractory B-cell lymphoma

pharmafile | January 21, 2020 | News story | Manufacturing and Production, Sales and Marketing Cancer, Polivy, Roche, lymphoma, pharma 

The European Commission has awarded conditional marketing approval to Roche’s Polivy (polatuzumab vedotin), it has been revealed. The therapy is authorised for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), when combined with bendamustine plus MabThera (rituximab), for patients who are not candidates for a haematopoietic stem cell transplant.

Roche announced that the Phase 1b/2 results submitted in support of the application were the first and only to show superiority of a drug versus the commonly used regimen of bendamustine plus MabThera alone. Specifically, the Polivy regimen generated complete response rates of 40% compared to just 17.5 with bendamustine plus MabThera alone, while overall survival was more than doubled to a median of 12.4 months compared to 4.7 months.

Additionally, median duration of response was recorded as 10.3 months with the Polivy regimen compared to 4.1 months.

“With this approval, people in the EU with relapsed or refractory diffuse large B-cell lymphoma will have the opportunity to benefit from this new Polivy combination,” remarked Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development. “For patients battling this aggressive disease, the prognosis is poor and few treatments are available. We are proud to bring this first-in-class treatment option to those who need it most.”

Advertisement

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

nerve-cell-2213009_960_720

Central nervous system cancer metastases – the evolution of diagnostics and treatment

The current forms of immunotherapy, how T cell therapy works and what the future holds

alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

The Gateway to Local Adoption Series

Latest content